Swissmedic authorised 46 human medicinal products with new active substances for the Swiss market in 2024 – an increase of 12% compared to the previous year.
This report summarises the most important information on these new authorisations as well as on the approved additional indications.
It provides a compact overview of the authorisation procedures used (including the reliance procedure, fast-track procedure and international procedures under Access and Orbis) as well as of the duration of the procedures and indications.
Swissmedic is also participating in two benchmarking studies conducting an international analysis of authorisation times with leading partner authorities. The findings of these studies will be published during the course of 2025.